stockrow
Saturday 7 November 2026
Export NBTX’s income statement to Excel — free account
Nanobiotix S.A. - Sponsored ADR
NBTX Healthcare Biotechnology
Nanobiotix S.A. - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $36.9 million.
30.60
0.58
+1.93%
Follow NBTX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 2 | 0 | 0 | 3 | 3 | 3 | 5 | 39 | (8) | 37 | 0 | +41.3% | — | — | — | — | |
| Gross margin, % | 0.00 | (37.14) | 0.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 0.00 | +100.0 pt | ||||||
| EBT | (27) | (35) | (39) | (57) | (38) | (56) | (60) | (43) | (74) | (27) | (122) | +0.1% | ||||||
| EBT margin, % | (1,636.19) | (11,667.74) | (28,962.07) | (2,003.63) | (1,336.80) | (1,775.50) | (1,194.12) | (109.32) | 946.06 | (73.51) | 0.00 | +1,562.7 pt | ||||||
| Net income | (23) | 0 | (35) | (57) | (38) | (56) | (60) | (43) | (74) | (27) | (130) | +1.8% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.11 | 0.02 | 0.01 | 0.13 | 0.12 | 0.09 | 0.14 | 1.06 | (0.16) | 0.77 | 0.00 | +24.5% | |||||
| Earnings | (1.51) | (1.81) | (1.78) | (2.63) | (1.60) | (1.60) | (1.76) | (1.17) | (1.56) | (0.57) | (3.32) | (10.2%) | ||||||
| Cash flow | (1.26) | (1.46) | (1.52) | (2.13) | (1.29) | (1.02) | (1.12) | (0.37) | (0.45) | (0.79) | 0.00 | (5.1%) | ||||||
| Capex | 0.00 | 0.00 | 0.00 | (0.07) | 0.00 | (0.01) | 0.00 | (0.01) | (0.02) | (0.01) | 0.00 | n/m | ||||||
| Free cash flow | (1.26) | (1.46) | (1.52) | (2.21) | (1.29) | (1.03) | (1.12) | (0.38) | (0.47) | (0.80) | 0.00 | (4.9%) | ||||||
| Book value | 1.18 | 3.01 | 0.82 | (0.10) | 3.30 | 0.91 | (0.82) | (0.05) | (1.50) | (2.00) | 0.00 | n/m | ||||||
| Shares, m | 15 | 17 | 20 | 22 | 24 | 35 | 35 | 37 | 47 | 48 | — | +13.5% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | 2,115.07 | 2,115.07 | 2,115.07 | 2,115.07 | 2,557.11 | 1,617.86 | 741.02 | 1,468.06 | 573.24 | 4,617.90 | 6,111.93 | 2,003.5 | ||||||
| P/B | 0.00 | 0.00 | 0.00 | 0.00 | 4.27 | 5.33 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.0 | ||||||
| EV/Sales | 2,239.44 | 2,239.44 | 2,239.44 | 2,239.44 | 1,917.58 | 1,146.44 | 803.15 | 1,167.28 | 537.50 | 4,526.00 | 5,356.43 | 1,905.6 | ||||||
| EV/FCF | (3.81) | (3.81) | (3.81) | (3.81) | (2.22) | (1.20) | (0.75) | (1.34) | (0.91) | (5.41) | (6.41) | (2.7) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (19) | (25) | (30) | (46) | (31) | (35) | (39) | (14) | (21) | (38) | (85) | +7.7% | |||||
| Capex | 0 | (2) | (1) | (2) | 0 | 0 | 0 | 0 | (1) | (1) | (2) | +4.3% | ||||||
| Free cash flow | (19) | (25) | (30) | (48) | (32) | (36) | (39) | (14) | (22) | (38) | (87) | +7.9% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 20 | 53 | 36 | 36 | 121 | 67 | 15 | 41 | 3 | 6 | 44 | (12.4%) | |||||
| Net debt | (16) | (51) | (18) | (39) | (136) | (99) | (44) | (81) | (54) | (60) | (129) | +15.6% | ||||||
| Shareholders’ equity | 18 | 53 | 16 | (2) | 80 | 32 | (28) | (2) | (71) | (96) | (39) | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (45.76) | (198.42) | (82.41) | (98.45) | (35.52) | (40.66) | (65.55) | (52.21) | (84.46) | (36.24) | 0.00 | +9.5 pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | (65.20) | (89.17) | (101.46) | (812.85) | (97.94) | (99.13) | (3,754.04) | 281.84 | 201.73 | 32.53 | 0.00 | +97.7 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | 90 | 88 | 100 | 102 | 102 | 108 | 97 | — | +1.3% | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 | 0.03 | 0.05 | 0.38 | (0.07) | 0.38 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2019 · fundamentals updated 2 Nov 2026
Nanobiotix S.A. - Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| SLS SELLAS Life Sciences Group, Inc. | $1.6B | — (loss-making) | — (loss-making) | −57.10% (below 0%: shrinking) | n/m | −3.52% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| KLRA Kailera Therapeutics, Inc. | $1.6B | — (loss-making) | — | — | n/m | −325.95% (below 0%: shrinking) | — | 0.00% | Compare |
| BRVE Braveheart Bio, Inc. | $1.6B | — | — | — | n/m | — | — | 0.00% | Compare |
| NTLA Intellia Therapeutics, Inc. | $1.6B | — (loss-making) | — (loss-making) | −48.03% (below 0%: shrinking) | n/m | −11.05% (below 0%: shrinking) | 100.00% | (1,707.73%) | Compare |
| RARE Ultragenyx Pharmaceutical Inc. | $1.5B | — (loss-making) | — (loss-making) | +8.13% (above 0%: growing) | n/m | +12.50% (above 0%: growing) | 81.50% | (63.58%) | Compare |
| NBTX Nanobiotix S.A. - Sponsored ADR | $1.5B | — (loss-making) | — | −71.69% (below 0%: shrinking) | n/m | −177.26% (below 0%: shrinking) | 0.00% | 0.00% | |
| PGEN Precigen, Inc. | $1.5B | 60.3× | 20.8× | +2,437.58% (above 0%: growing) | n/m | +140.34% (above 0%: growing) | 91.22% | 52.13% | Compare |
| NUVB Nuvation Bio Inc. | $1.5B | — (loss-making) | — (loss-making) | +242.61% (above 0%: growing) | n/m | +34.07% (above 0%: growing) | 73.46% | (93.90%) | Compare |
| ADRX ADARx Pharmaceuticals, Inc. | $1.5B | — | — | — | — | — | — | — | Compare |
| Median of peers | $1.6B | — | — | +8.13% | — | +4.49% | 81.50% | 0.00% |